(Q38093224)

28 August 2017

title

Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer (English)

1 reference

28 August 2017

1 reference

2

1 reference

28 August 2017

Ciara C O'Sullivan

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

27 March 2013

1 reference

Expert Opinion on Biological Therapy

28 August 2017

published in

1 reference

28 August 2017

volume

13

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

779-790

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

ErbB2 is essential in the prevention of dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Recurrent glioblastoma: not only surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

AE37: a novel T-cell-eliciting vaccine for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Antibody-drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.783007

10.1517/14712598.2013.783007

21 January 2018

Identifiers

DOI

1 reference

release_qo63cnxmk5cttjrch5ny77rllq

28 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qo63cnxmk5cttjrch5ny77rllq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference